Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis

BACKGROUND: The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited. CASE SUMMARY: We report the case of a patient with decompens...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Zhang, Tong, Yan, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266031/
https://www.ncbi.nlm.nih.gov/pubmed/27930559
http://dx.doi.org/10.1097/MD.0000000000005555
_version_ 1782500391435370496
author Liu, Hui
Zhang, Tong
Yan, Yan
author_facet Liu, Hui
Zhang, Tong
Yan, Yan
author_sort Liu, Hui
collection PubMed
description BACKGROUND: The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited. CASE SUMMARY: We report the case of a patient with decompensated cirrhosis induced by autoimmune liver disease, whose condition rapidly deteriorated following AHC virus infection. The patient received sofosbuvir and ribavirin combination treatment for 12 weeks. Serum hepatitis C virus RNA remained undetectable 36 weeks after discontinuing sofosbuvir and ribavirin. CONCLUSION: Our findings support the use of sofosbuvir and ribavirin as a treatment in AHC patients with decompensated cirrhosis.
format Online
Article
Text
id pubmed-5266031
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52660312017-02-06 Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis Liu, Hui Zhang, Tong Yan, Yan Medicine (Baltimore) 4500 BACKGROUND: The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited. CASE SUMMARY: We report the case of a patient with decompensated cirrhosis induced by autoimmune liver disease, whose condition rapidly deteriorated following AHC virus infection. The patient received sofosbuvir and ribavirin combination treatment for 12 weeks. Serum hepatitis C virus RNA remained undetectable 36 weeks after discontinuing sofosbuvir and ribavirin. CONCLUSION: Our findings support the use of sofosbuvir and ribavirin as a treatment in AHC patients with decompensated cirrhosis. Wolters Kluwer Health 2016-12-09 /pmc/articles/PMC5266031/ /pubmed/27930559 http://dx.doi.org/10.1097/MD.0000000000005555 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4500
Liu, Hui
Zhang, Tong
Yan, Yan
Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title_full Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title_fullStr Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title_full_unstemmed Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title_short Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
title_sort sofosbuvir and ribavirin in acute hepatitis c–infected patient with decompensated cirrhosis
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266031/
https://www.ncbi.nlm.nih.gov/pubmed/27930559
http://dx.doi.org/10.1097/MD.0000000000005555
work_keys_str_mv AT liuhui sofosbuvirandribavirininacutehepatitiscinfectedpatientwithdecompensatedcirrhosis
AT zhangtong sofosbuvirandribavirininacutehepatitiscinfectedpatientwithdecompensatedcirrhosis
AT yanyan sofosbuvirandribavirininacutehepatitiscinfectedpatientwithdecompensatedcirrhosis

Ejemplares similares